Insider Selling: Privia Health Group, Inc. (NASDAQ:PRVA) Director Sells 18,153 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) Director William M. Sullivan sold 18,153 shares of the firm’s stock in a transaction on Friday, April 28th. The shares were sold at an average price of $27.36, for a total value of $496,666.08. Following the transaction, the director now directly owns 5,699,859 shares of the company’s stock, valued at approximately $155,948,142.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Privia Health Group Stock Up 6.1 %

Privia Health Group stock opened at $29.09 on Friday. The business has a 50-day simple moving average of $27.18 and a two-hundred day simple moving average of $26.42. The company has a market cap of $3.35 billion, a P/E ratio of -264.45, a P/E/G ratio of 5.09 and a beta of 0.77. Privia Health Group, Inc. has a 52-week low of $17.99 and a 52-week high of $44.64.

Privia Health Group (NASDAQ:PRVA – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.17. The business had revenue of $364.42 million during the quarter, compared to the consensus estimate of $337.16 million. Privia Health Group had a negative return on equity of 0.25% and a negative net margin of 0.63%. Research analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PRVA. The Goldman Sachs Group began coverage on Privia Health Group in a research report on Friday, February 3rd. They issued a “buy” rating and a $32.00 price target for the company. Royal Bank of Canada began coverage on Privia Health Group in a research report on Thursday, March 9th. They issued an “outperform” rating and a $36.00 price target for the company. Credit Suisse Group reaffirmed an “outperform” rating and issued a $41.00 price target on shares of Privia Health Group in a research report on Tuesday, March 7th. SVB Securities lifted their price target on Privia Health Group from $39.00 to $40.00 in a research report on Friday. Finally, BTIG Research lowered their price target on Privia Health Group from $45.00 to $40.00 in a research report on Monday, January 9th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $39.19.

Institutional Investors Weigh In On Privia Health Group

A number of large investors have recently made changes to their positions in the company. Truist Financial Corp bought a new stake in shares of Privia Health Group during the 1st quarter valued at about $312,000. Assetmark Inc. grew its stake in shares of Privia Health Group by 148.9% during the 1st quarter. Assetmark Inc. now owns 3,880 shares of the company’s stock valued at $107,000 after acquiring an additional 2,321 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of Privia Health Group by 38.1% during the 1st quarter. Essex Investment Management Co. LLC now owns 4,361 shares of the company’s stock valued at $120,000 after acquiring an additional 1,202 shares during the period. Barclays PLC grew its stake in shares of Privia Health Group by 40.6% during the 1st quarter. Barclays PLC now owns 56,870 shares of the company’s stock valued at $1,571,000 after acquiring an additional 16,421 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Privia Health Group by 13.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,680 shares of the company’s stock valued at $626,000 after acquiring an additional 2,752 shares during the period. 66.83% of the stock is currently owned by institutional investors.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.